close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CorMedix Inc. - Common Stock (NQ:CRMD)

11.88 -0.29 (-2.34%)
Streaming Delayed Price Updated: 3:00 PM EDT, Oct 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about CorMedix Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
CorMedix Inc (NASDAQ:CRMD) Fits a Proven Growth Strategy with Strong Fundamentals
CorMedix Inc. fits a proven growth investing strategy with explosive revenue growth, soaring profits, and strong analyst revisions, signaling high potential. 
Via Chartmill
CRMD Stock Is The Talk Of The Town Today: What’s The Latest 2025 Revenue Forecast?
Via Stocktwits
CorMedix Inc (NASDAQ:CRMD) Identified as a Top Growth Stock Candidate
CorMedix Inc (CRMD) identified as a top growth stock using Louis Navellier's strategy, showing explosive revenue growth, soaring earnings estimates, and strong profitability. 
Via Chartmill
Analyst Expectations For Cormedix's Future
 
Via Benzinga
CorMedix Inc (NASDAQ:CRMD) Embodies a Proven Growth Investing Strategy
CorMedix (CRMD) excels in Louis Navellier's growth strategy with massive revenue growth, soaring earnings, and high ROE, making it a top stock to watch. 
Via Chartmill
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
CorMedix Strikes $300M Deal For Melinta Therapeutics, Retail Calls It A ‘Wonderful Acquisition’
Via Stocktwits
Earnings Scheduled For May 6, 2025
 
Via Benzinga
Earnings Preview For Cormedix
 
Via Benzinga
CORMEDIX INC (NASDAQ:CRMD) – A High-Growth Stock Aligned with Louis Navellier’s Investment Strategy
Discover how CORMEDIX INC (CRMD) aligns with Louis Navellier’s growth investing strategy, showcasing strong earnings momentum, rapid revenue growth, and high ROE for potential stock gains. 
Via Chartmill
Elliott Management Bets Against S&P 500, Nasdaq 100, Nvidia Stock In Second Quarter
Elliott Management places new bets against the market in the second quarter, while taking a new long position in Hewlett Packard Enterprise. 
Via Benzinga
Topics Stocks
Deal Dispatch: Performance Food Group And Claire's Lead A Week Of Big Auctions, Retail Woes
Performance Food rejects offer; Lufthansa drops Air Europa bid; NFL inks deal with ESPN; Claire's files bankruptcy amid retail struggles. 
Via Benzinga
Topics Bankruptcy
CorMedix Inc (NASDAQ:CRMD) Reports Strong Q2 2025 Earnings, Beats Estimates and Announces Strategic Acquisition
CorMedix Inc (CRMD) reported strong Q2 2025 earnings, beating revenue and EPS estimates, with shares rising in pre-market trading. The company also announced the acquisition of Melinta Therapeutics. 
Via Chartmill
Topics Earnings
CorMedix Analyst Says Investors Could Be Further Rewarded
CorMedix boosts Q2 sales forecast as a major dialysis client accelerates DefenCath use, prompting positive analyst coverage and growth outlook. 
Via Benzinga
This CorMedix Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Monday
 
Via Benzinga
Concentrix Posts Downbeat Earnings, Joins CorMedix And Other Big Stocks Moving Lower In Friday's Pre-Market Session
 
Via Benzinga
Stay updated with the stocks that are on the move in today's pre-market session.
The US market is yet to commence its session on Friday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements. 
Via Chartmill
CorMedix Stock Tumbles After $85M Stock Sale; But Retail Sees Bargain In DefenCath Bet
The offering follows an upward revision to CorMedix’s Q2 revenue forecast, driven by faster-than-expected rollout of its FDA-approved DefenCath therapy across an extensive dialysis network. 
Via Stocktwits
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
Get insights into the top gainers and losers of Thursday's after-hours session.
After the closing bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session. 
Via Chartmill
Applied Materials To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Tuesday
 
Via Benzinga
CorMedix Lifts Q2 Outlook As Dialysis Partner Expands DefenCath Use; Needham Raises PT To $20
DefenCath, CorMedix’s lead product, was launched in hospitals in April 2024 and in outpatient settings in July 2024 following FDA approval. 
Via Stocktwits
CorMedix Spikes To Four-Year High On A Surprise Deal For Its Leading Drug
CorMedix shares bounded to a four-year high Monday after the biotech company inked an expanded deal for its leading drug. 
Via Investor's Business Daily
CorMedix Stock Hits New 52-Week High On Updated Guidance: The Details
CorMedix Inc (NASDAQ:CRMD) shares are hitting new 52-week highs on Monday after the company raised its sales guidance for the second quarter. 
Via Benzinga
Kroger Posts Better-Than-Expected Earnings, Joins Couchbase, CarMax And Other Big Stocks Moving Higher On Friday
 
Via Benzinga
CorMedix Q1 Earnings Trump Estimates: Retail’s Overjoyed
The company reported net revenue of $39.1 million for the first quarter from the sales of DefenCath, above an analyst estimate of $36, as per Finchat data. 
Via Stocktwits
Topics Earnings Government
CorMedix Stock Rises After Preliminary Q1 Results Exceeds Expectations: Retail’s Elated
The company expects quarterly adjusted earnings before interest, taxes, depreciation, and amortisation (EBITDA) to exceed $22.5 million once final numbers are reported, exceeding expectations of $14.78... 
Via Stocktwits
Marvell Technology, Nvidia, Tesla, Apple And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
CorMedix (CRMD) Q4 2024 Earnings Call Transcript
CRMD earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
Which stocks are experiencing notable movement on Tuesday?
Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements. 
Via Chartmill
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today